SEC Form 4 · accession 0001567619-18-002765
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A Meier
Director
Period of report
Sep 13, 2018
Accepted (ET)
Sep 17, 2018 · 7:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 13, 2018 | M | 12,000 | $21.51 | A | 81,610 | D | |
| Common Stock | Sep 13, 2018 | M | 3,000 | $21.51 | A | 84,610 | D | |
| Common Stock | Sep 13, 2018 | S | 2,800 | $99.24 | D | 81,810 | D | |
| Common Stock | Sep 13, 2018 | S | 200 | $99.25 | D | 81,610 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1 | $21.51 | Sep 13, 2018 | M | 3,000 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 3,000 | 12,000 | D |
| Stock Option (Right to buy Common Stock)F1 | $21.51 | Sep 13, 2018 | M | 12,000 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 12,000 | 0 | D |
Explanation of responses
- F1Reflects the number of options outstanding after the transactions from this specific stock option grant.